Translational Psychiatry · 2025 · 12 citations · 57 references
MedicineNeurosciencePharmacologyBehavioral NeuroscienceNeuropharmacologyPsychopharmacologyNeurochemical PharmacologyNeuromodulationNeurotransmissionSerotonergic Pharmacology5-Hydroxytryptamine Receptor PharmacologyFunctional Magnetic Resonance ImagingMagnetic ResonancePharmacodynamic MechanismsPrefrontal Cortex FunctionPrefrontal Cortex Involvement
Psilocybin, and its active metabolite psilocin, have seen renewed interest due to studies suggesting potential therapeutic utility. 5-Hydroxytryptamine2A receptors (5-HT 2A Rs) are primary mediators of the psychoactive effects of psychedelics in animals and humans, but the underlying neurobiological mechanisms remain poorly understood. Functional magnetic resonance imaging identified significant psilocin-induced increases in medial prefrontal cortex (mPFC) activity, a site of enriched 5-HT 2A R expression. We identified a population of 5-HT 2A R neurons in the prelimbic/anterior cingulate mPFC. Psilocin and the 5-HT 2A R-selective compound 25-CN-NBOH increased excitability, and stimulated firing across a range of current injections in these neurons that was both 5-HT 2A R and Gα q dependent. Similar effects were observed with a novel, non-hallucinogenic psychedelic compound. These findings provide valuable insight into the specific role of 5-HT 2A R-containing neurons in psychedelic-associated plasticity in mPFC regions that are likely implicated in the clinical effects of psychedelics and further identify membrane-bound 5-HT 2A Rs and subsequent intracellular Gα q signaling as therapeutic targets.
57
Roland R. Griffiths, Matthew W. Johnson, Michael A. Carducci et al. · Journal of Psychopharmacology · 2016 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +10
Predicting new molecular targets for known drugs
Michael J. Keiser, Vincent Setola, John J. Irwin et al. · Nature · 2009 · 1.7K citations
Stephen Ross, Anthony P. Bossis, Jeffrey Guss et al. · Journal of Psychopharmacology · 2016 · 1.7K citations · Full text
Medicine, Oncology, Pharmacology +17
Trial of Psilocybin versus Escitalopram for Depression
Robin Carhart‐Harris, Bruna Giribaldi, Rosalind Watts et al. · New England Journal of Medicine · 2021 · 1.4K citations